Vaccines Shakeup Continues In China: NT Pharma Backs Away From GSK
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - China's largest vaccine distributor China NT Pharma Group announced Aug. 17 it will not renew its master distribution contract with its largest customer GlaxoSmithKline PLC, in part, it appears, due to burdens created by the new China Pharmacopeia that was issued at the end of 2010
You may also be interested in...
China’s Best Shot: GSK, Novartis Gear Up For Vaccine Prime Time
With its large population, one-child policy and increasing emphasis on preventative care, China is poised for a vaccine boom. The catalyst for growth may come from the expected modernization of the country’s massive national immunization program.
Merck Ties Up With Zhifei To Distribute Gardasil In China, But What Happened To Sinopharm?
Merck has expanded its collaboration with Zhifei, its vaccine partner in China, by signing a three-year RMB 4.5 billion distribution deal for HPV vaccine Gardasil. But left unanswered is whether Merck will walk away from a partnership with Sinopharm it had previously emphasized.
Merck Ties Up With Zhifei To Distribute Gardasil In China, But What Happened To Sinopharm?
Merck has expanded its collaboration with Zhifei, its vaccine partner in China, by signing a three-year RMB 4.5 billion distribution deal for HPV vaccine Gardasil. But left unanswered is whether Merck will walk away from an intended partnership with Sinopharm it had previously emphasized.